Our Technology

Engineered for Precision. Designed for Earlier Action.

Our implantable sensing technology combines automatic, daily physiological monitoring with predictive analytics to detect cardiac deterioration earlier and support proactive, personalized care.

Explore the technology
Research & Innovation

One connected system

From daily monitoring to informed clinical action.

Four connected steps bring physiological information from the patient’s home to the care team.

Illustration of a patient at home with a circular chest zoom, a home gateway transmitting data to the secure MERCURE cloud, and a clinician reviewing the resulting information

  1. Capture cardiac signals

    The SCOUT implant is designed to collect daily physiological information automatically.


  2. Connect from home

    A home gateway links the implant to the data infrastructure through available network connections.


  3. Transform data into insight

    MERCURE analyzes complementary signals to estimate information associated with cardiac filling pressures.


  4. Support earlier assessment

    Longitudinal information is designed to help care teams assess meaningful changes in cardiac status.

  

SCOUT implant

Small implant.
Continuous insight.

A compact, multi-sensor subcutaneous implant designed for long-term, automatic cardiac monitoring.

CardiaMetrics SCOUT implant compared with a AAA battery. SCOUT measures up to 43 by 15 by 7 millimeters, while the AAA battery is 44.5 millimeters long.
SCOUT is comparable in length to a standard AAA battery. Illustrative comparison, not actual size.

SCOUT combines electrical and mechanical cardiac sensing, long-term power management and wireless communication within a compact, biocompatible titanium enclosure.

  • Multi-sensor ECG + 3-axis accelerometry
  • Up to 6 years* Targeted battery longevity
  • Minimally invasive Subcutaneous, ILR-like form factor
  • Automatic monitoring BLE connectivity with HOME Gateway
Explore the engineering

Physiological sensing: SCOUT integrates an ECG sensor and a 3-axis accelerometer to acquire complementary information on cardiac electrical activity, mechanical activity and movement.

Implant architecture: Designed for subcutaneous placement, SCOUT features a biocompatible titanium enclosure with a form factor comparable in length to implantable loop recorders. Its maximum dimensions are 43 × 15 × 7 mm.

Power and longevity: The system targets up to six years of battery operation, subject to validation of the final device configuration and operating conditions.

Automatic connectivity: Bluetooth Low Energy enables communication with the HOME Gateway, supporting a monitoring workflow designed to minimize routine patient interaction.

*Six-year battery life is a development target, not a validated or guaranteed product specification. SCOUT is an investigational technology.

Proprietary technology

From physiological signals to trusted clinical insight.

MERCURE AI is CardiaMetrics' proprietary intelligence platform, designed to combine multi-modal physiological signals with contextual information and machine learning. By filtering and interpreting data in context, MERCURE aims to deliver more reliable, clinically relevant information.

MERCURE AI processes multi-modal physiological signals and contextual information to support clinically relevant insights

Input

Multi-modal data

Complementary physiological signals and contextual information provide a broader understanding of the patient's cardiac status and measurement conditions.

Intelligence

Context-aware AI

Proprietary algorithms process and filter physiological signals, taking measurement context into account to identify potentially unreliable data and reduce misleading interpretations.

Output

Confidence-informed insight

MERCURE is designed to provide clinically relevant information together with an assessment of data reliability, helping care teams make more informed decisions about patient management.

Technology under clinical development. MERCURE's contextual processing, reliability assessment and clinical utility are subject to ongoing evaluation and validation.

Why hemodynamics matter

Hemodynamic changes can occur before symptoms become apparent.

Changes in cardiac filling pressures can provide important information about evolving heart failure. CardiaMetrics is developing a way to estimate these changes remotely, creating an opportunity for earlier clinical assessment.

Longitudinal monitoring

Estimated cardiac filling pressure

Hemodynamic parameter PCWP
Conceptual progression of cardiac filling pressure An illustrative curve rises from a stable baseline through increasing filling pressure toward symptoms and potential hospitalization. The highlighted early period represents an opportunity for earlier assessment. This diagram contains no measured patient data.
Increasing filling pressure → Conceptual illustration · not patient data
The opportunity for earlier insight Estimated hemodynamic changes may provide information before overt clinical deterioration.

  1. Stable

    Baseline cardiac status


  2. Rising filling pressure

    Hemodynamic changes may begin


  3. Symptoms

    Clinical deterioration becomes apparent


  4. Potential hospitalization

    Acute care may become necessary

The opportunity

Move from reacting to symptoms toward earlier clinical assessment.

By providing longitudinal information on estimated hemodynamic changes, CardiaMetrics is designed to help care teams identify meaningful changes in cardiac status earlier and support proactive clinical decision-making.

Explore Clinical Validation

Conceptual representation of heart failure progression.

Connected monitoring

Seamless connectivity.
Wherever life happens.

CardiaMetrics is developing flexible gateway solutions to connect SCOUT with the remote monitoring pathway, at home and beyond.

Concept illustration of the CardiaMetrics HOME Gateway
Concept illustration. Final product design may differ.

  • Implant link

    Communicates with SCOUT using Bluetooth Low Energy.

  • Flexible connectivity

    Supports data transfer through available network connectivity.

  • Automatic operation

    Designed to transfer monitoring data with minimal routine patient interaction.

  • Secure updates

    Designed to support secure software maintenance and updates.

Flexible monitoring

Connected at home. Connected on the move.

Two complementary gateway options perform the same connectivity role, supporting automatic communication between SCOUT and the CardiaMetrics monitoring platform.

Dedicated hardware

HOME Gateway

A dedicated connectivity device designed for automatic communication with SCOUT and secure data transfer from the patient's home.

Patient-device application

Mobile Gateway

An application installed on the patient's own device, designed to perform the same gateway function as the dedicated hardware, enabling connected monitoring beyond the home.

Secure data infrastructure

Built for security.
Designed for regulatory adaptability.

CardiaMetrics is developing a secure, adaptable health-data infrastructure designed to protect sensitive patient information and accommodate the healthcare and data protection requirements of each country in which the system is deployed.

Protected health-data pathway

Conceptual architecture illustrating protected physiological data handling and controlled clinical access.

  • Data protection

    Designed to support secure transmission, storage and controlled access to sensitive health information.

  • Local regulatory alignment

    Infrastructure designed to accommodate applicable healthcare and data protection requirements in each deployment country.

  • GDPR / RGPD

    Developed with European data protection principles in mind, including privacy, data governance and the protection of personal health information.

  • Adaptable infrastructure

    A flexible architecture designed to support different deployment environments, data governance requirements and country-specific healthcare regulations.

Regulatory adaptability by design. CardiaMetrics is developing its infrastructure to support applicable data protection and healthcare regulations in each intended market, including GDPR in the European Union. Compliance with local requirements will be assessed and implemented according to the jurisdiction and deployment context.

Research & Innovation

Technology is only as meaningful as the evidence behind it.

Explore the clinical research, hospital collaborations and intellectual property supporting the development of CardiaMetrics technology.


  1. Clinical research

    Prospective studies with leading hospital partners.


  2. Scientific evidence

    Research evaluating physiological and hemodynamic information.


  3. Protected innovation

    A growing intellectual property portfolio.

Explore Research & Innovation